Zacks Research Has Weak Forecast for AbbVie FY2025 Earnings

AbbVie Inc. (NYSE:ABBV) – Zacks Research decreased their FY2025 earnings per share estimates for shares of AbbVie in a research note issued to investors on Wednesday, January 14th. Zacks Research analyst Team now expects that the company will earn $9.94 per share for the year, down from their prior estimate of $10.64. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie’s Q4 2025 earnings at $2.65 EPS, Q4 2026 earnings at $3.69 EPS and Q4 2027 earnings at $4.15 EPS.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter last year, the company earned $3.00 EPS. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.

ABBV has been the subject of several other reports. Morgan Stanley boosted their price objective on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Raymond James Financial set a $256.00 price target on AbbVie in a research report on Monday, November 3rd. Bank of America increased their price objective on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. Finally, Scotiabank assumed coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $248.11.

AbbVie Stock Down 0.2%

ABBV opened at $213.90 on Monday. The company has a market cap of $378.04 billion, a PE ratio of 162.05, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36. AbbVie has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a 50-day moving average price of $226.50 and a 200 day moving average price of $216.99.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is currently 524.24%.

Institutional Trading of AbbVie

Hedge funds have recently made changes to their positions in the company. Ellenbecker Investment Group raised its position in AbbVie by 0.8% in the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after purchasing an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA raised its holdings in AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after buying an additional 45 shares during the period. Matthew Goff Investment Advisor LLC raised its holdings in AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after buying an additional 45 shares during the period. Centennial Wealth Advisory LLC lifted its position in AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after buying an additional 45 shares during the last quarter. Finally, Willner & Heller LLC boosted its stake in AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after buying an additional 46 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.